Grey address deposits 675.31 BTC to CEX Prime, worth about $61.69 million
On 3 March, chain data showed that the Grayscale Bitcoin Trust (GBT) address made a change and transferred 675.31 BTC to CEX Prime and another address at 22:46 on 3 March 2025, with a current valuation of approximately $61.69 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Advanced Drainage Systems to buy StormTrap for about $530 million
ADS agreed to buy StormTrap Investments from PSP Capital for about $530 million, or about $450 million adjusted for expected tax benefits. Deal expands ADS into large-volume, space-constrained stormwater storage and treatment systems, strengthening its offering in commercial and infrastructure projects. StormTrap posted about $165 million revenue, about $40 million adjusted EBITDA for the 12 months ended July 2026. Net valuation implies about 10x adjusted EBITDA, including expected run-rate cost synergies; funding set from cash and existing credit lines. Closing targeted for the fourth quarter of calendar 2026, subject to customary closing conditions and required regulatory approvals. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADS - Advanced Drainage Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610050645BIZWIRE_USPR_____20261005_BW997833) on October 05, 2026, and is solely responsible for the information contained therein.
BUZZ - Broker perspectives: Schneider - The rationale for PTC trading is "clear," but AI, integration, and financing pressures are imminent
October 5th - Schneider Electric (SCHN.PA) will acquire US software company PTC (PTC.O) for $22.6 billions, marking the company’s largest deal ever and signifying its further commitment to the industrial artificial intelligence sector. The announcement of the deal, which includes raising substantial equity and debt financing, led to a roughly 9% drop in Schneider’s share price; however, analysts generally recognized the logic behind this move amid AI anxieties and execution risks. Jefferies analysts noted there is a “very clear” strategic rationale, as it fills one of the remaining gaps in Schneider’s software portfolio. JPMorgan pointed out that this “complementary” fit should also help ease antitrust scrutiny. Baird added that, among all bidders, Schneider Electric’s industrial rationale is the strongest. However, both Jefferies and RBC highlighted the industry’s concerns about disruption from artificial intelligence—concerns that allowed Schneider to acquire PTC at its lowest valuation in a decade—which could potentially affect the French company’s share price post-deal. RBC added that the significant debt needed to finance the transaction may reignite worries over Schneider’s longstanding spending issues. JPMorgan noted the complexity of the integration process, pointing out that large-scale M&A typically receives a lukewarm response in Europe, “even though Schneider Electric’s deals have generally proven to be strategically farsighted.” (For readers who are not native English speakers, Reuters has provided automated translation of its reports in several languages for convenience. As automated translation may contain errors or fail to convey full context, Reuters does not guarantee the accuracy of such automated texts and accepts no responsibility for any damages or losses resulting from their use.)
BUZZ - Vaxcyte shares soar following successful late-stage clinical trial for pneumococcal vaccine
October 5 – Vaxcyte (PCVX.O) shares surged 26% pre-market to $71.17. Vaxcyte announced that its 31-valent pneumococcal vaccine VAX-31 met all primary endpoints in a late-stage clinical trial, and generated immune responses comparable to or stronger than Pfizer’s Prevnar 20 and Merck’s Capvaxive. The safety and tolerability of the vaccine were similar to existing vaccines. Vaxcyte expects results from two additional late-stage clinical trials in the first half of 2027, and plans to submit a marketing application to the FDA in the first half of 2028. As of the previous trading session’s close, the stock had risen 22.4% year-to-date.
Linde to release Q3 2026 results, hosts investor conference call and webcast
Linde will publish third-quarter 2026 results on Oct. 29, 2026 by 6:00 a.m. EDT (11:00 a.m. CET). Conference call webcast set for Oct. 29, 2026 at 9:00 a.m. EDT (2:00 p.m. CET). Web replay available from Oct. 29, 2026 at 10:30 a.m. EDT (3:30 p.m. CET) via https://www.linde.com/investors/financial-reports. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Linde plc published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2409690_en) on October 05, 2026, and is solely responsible for the information contained therein.